BridgeBio Pharma, Inc.
76.08USD
+1.3200 (+1.77%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 77.6M | 9.3M | 221.9M | 502.1M | 1.0B | 1.7B |
| Q1 | 1.7M | 1.8M | 211.1M | 116.6M | 194.5M | — |
| Q2 | 73.7M | 1.6M | 2.2M | 110.6M | 243.7M | — |
| Q3 | 338.0K | 4.1M | 2.7M | 120.7M | 268.4M | — |
| Q4 | 1.9M* | 1.7M* | 5.9M* | 154.2M* | 313.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -3.26 | -3.95 | -2.88 | -3.78 | -2.58 | .027 |
| Q1 | -1.35 | -.920 | -.200 | -.880 | -.840 | — |
| Q2 | -.070 | -.980 | -.390 | -.950 | -.780 | — |
| Q3 | -.930 | -1.08 | -.860 | -.950 | -.629 | — |
| Q4 | -.953* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -1.05* |
| -1.44* |
| -1.02* |
| -.435 |
| — |